Biochemical Screening for Nonadherence Is Associated with Blood Pressure Reduction and Improvement in Adherence

Hypertension

Volumn 70, Issue 5, 2017, Pages 1042-1048

  Gupta, Pankaj ^a,b,c,d   Patel, Prashanth ^a,b,c   Štrauch, Branislav ^f   Lai, Florence Y ^b,c   Akbarov, Artur ^d,f   Gulsin, Gaurav S ^a,b   Beech, Alison ^b   Marešová, Věra ^e   Topham, Peter S ^a   Stanley, Adrian ^a   Thurston, Herbert ^a   Smith, Paul R ^a   Horne, Robert ^g   Widimský, Jiří ^f   Keavney, Bernard ^d,h   Heagerty, Anthony ^d,h   Samani, Nilesh J ^b,c   Williams, Bryan ^g,i   Tomaszewski, MacIej ^d,h  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c National Institute for Health Research Leicester Cardiovascular Biomedical Research Unit ^*  (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e Hypertension Centre   (United Kingdom)

^f CHARLES UNIVERSITY   (Czech Republic)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

ⁱ and University of Bristol   (United Kingdom)

Author keywords

adherence; antihypertensive agents; blood pressure; chromatography, liquid; hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BIOCHEMICAL ANALYSIS; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CARDIAC PATIENT; CZECH REPUBLIC; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING TEST; TERTIARY CARE CENTER; TREATMENT REFUSAL; URINALYSIS; URINE SAMPLING; AGED; BLOOD; DRUG EFFECTS; LIQUID CHROMATOGRAPHY; MEDICATION COMPLIANCE; MEDICATION THERAPY MANAGEMENT; PROCEDURES; PSYCHOLOGY; STANDARDS; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; UNITED KINGDOM; URINE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BIOMARKERS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CHROMATOGRAPHY, LIQUID; CZECH REPUBLIC; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); QUALITY IMPROVEMENT; UNITED KINGDOM;

EID: 85031807726     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.117.09631     Document Type: Article

References (43)

1. WHO. A global brief on hypertension. who.int/cardiovascular-diseases/publications/global-brief-hypertension. Accessed January 16, 2017.
2. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955-1964.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., Jones DW, Materson BJ, Oparil S, Wright JT Jr., Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572. doi: 10.1001/jama.289.19.2560.
4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-Analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
5. Kotseva K, Wood D, De Bacquer D, et al; EUROASPIRE Investigators. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23:636-648. doi: 10.1177/2047487315569401.
6. Yoon S, Fryar C, Carroll M. Hypertension prevalence and control among adults: United States, 2011-2014. NCHS Data Brief, no 220. Hyattsville, MD: National Center for Health Statistics. www.cdc.gov/nchs/data/databriefs/db220.htm. Accessed December 18, 2016.
7. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, Cesana G, Mancia G. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008;26:819-824. doi: 10.1097/HJH.0b013e3282f4edd7.
8. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766-774. doi: 10.1097/HJH.0b013e32835e2286.
9. Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, Stricker B, Mendis S, Hofman A, Mant J, Franco OH. Adherence to cardiovascular therapy: a meta-Analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940-2948. doi: 10.1093/eurheartj/eht295.
10. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, Samani NJ, Gupta P, Madira W, Stanley A, Williams B. High rates of nonadherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100:855-861. doi: 10.1136/heartjnl-2013-305063.
11. Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-tocontrol arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-Adherence to recommended therapy. Hypertens Res. 2011;34:87-90. doi: 10.1038/hr.2010.183.
12. Strauch B, Petrák O, Zelinka T, Rosa J, Somlóová Z, Indra T, Chytil L, Mareŝová V, Kurcová I, Holaj R, Wichterle D, Widimský J Jr. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31:2455-2461. doi: 10.1097/HJH.0b013e3283652c61.
13. Brinker S, Pandey A, Ayers C, Price A, Raheja P, Arbique D, Das SR, Halm EA, Kaplan NM, Vongpatanasin W. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol. 2014;63:834-835. doi: 10.1016/j.jacc.2013.10.067.
14. Rosa J, Zelinka T, Petrák O, Ŝtrauch B, Ŝomlóová Z, Indra T, Holaj R, Curila K, Touŝek P, Ŝenitko M, Widimský P, Widimský J Jr. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically? J Hum Hypertens. 2014;28:684-688. doi: 10.1038/jhh.2014.3.
15. Ewen S, Meyer MR, Cremers B, Laufs U, Helfer AG, Linz D, Kindermann I, Ukena C, Burnier M, Wagenpfeil S, Maurer HH, Böhm M, Mahfoud F. Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Res Cardiol. 2015;104:1097-1105. doi: 10.1007/s00392-015-0905-5.
16. Pandey A, Raza F, Velasco A, Brinker S, Ayers C, Das SR, Morisky DE, Halm EA, Vongpatanasin W. Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatmentresistant hypertension. J Am Soc Hypertens. 2015;9:420-426.e2. doi: 10.1016/j.jash.2015.04.004.
17. Patel P, Gupta PK, White CM, Stanley AG, Williams B, Tomaszewski M. Screening for non-Adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation. J Hum Hypertens. 2016;30:368-373. doi: 10.1038/jhh.2015.103.
18. Schmieder RE, Ott C, Schmid A, Friedrich S, Kistner I, Ditting T, Veelken R, Uder M, Toennes SW. Adherence to antihypertensive medication in treatment-resistant hypertension undergoing renal denervation. J Am Heart Assoc. 2016;5:e002343. doi:10.1161/JAHA.115.002343.
19. Gupta P, Patel P, Ŝtrauch B, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension. 2017;69:1113-1120. doi: 10.1161/HYPERTENSIONAHA.116.08729.
20. NICE. CG127 hypertension: clinical management of primary hypertension in adults. www.nice.org.uk/CG127. Accessed February 16, 2017.
21. FilipovskýJ, Widimský J Jr., Ceral J, CífkováR, Horký K, Linhart A, Monhart V, RosolováH, Seidlerová J, Soucek M, Ŝpinar J, Vítovec J, Widimský J. Diagnostické a lécebné postupy u arteriální hypertenze-verze 2012. Doporucení ceské spolecnosti pro hypertenzi. Hypertenze a kardiovaskulární prevence. 2012;3:1-16.
22. Chytil L, Cvacka J, Mareŝová V, Ŝtrauch B, Widimský J Jr., Ŝtícha M, Slanar O. Development of a fast LC-MS/MS method for quantification of rilmenidine in human serum: elucidation of fragmentation pathways by HRMS. J Mass Spectrom. 2010;45:1179-1185. doi: 10.1002/jms.1809.
23. Iriarte G, Gonzalez O, Ferreirós N, Maguregui MI, Alonso RM, Jiménez RM. Validation of a fast liquid chromatography-UV method for the analysis of drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:3045-3053. doi: 10.1016/j.jchromb.2009.07.018.
24. Chytil L, Strauch B, Cvacka J, Mareŝová V, Widimský J Jr., Holaj R, Slanar O. Determination of doxazosin and verapamil in human serum by fast LC-MS/MS: application to document non-compliance of patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:3167-3173. doi: 10.1016/j.jchromb.2010.09.032.
25. Florczak E, Tokarczyk B, Warchol-Celinska E, Szwench-Pietrasz E, Prejbisz A, Gosk M, Kabat M, Narkiewicz K, Januszewicz A, Kala M. Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis. A subgroup evaluation of the RESIST-POL study. Pol Arch Med Wewn. 2015;125:65-72.
26. Nakagawa S, Schielzeth H. A general and simple method for obtaining R2 from generalized linear mixed-effects models. Methods Ecol Evol. 2013;4:133-142.
27. R Core Team. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. https://www.Rproject. org. Accessed December 12, 2016.
28. Bates D, Maechler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67:1-42.
29. Dowle M, Srinivasan A, Short T, Lianoglou S. with contributions from Saporta R, Antonyan E. data.table: extension of Data frame. R package version 1.9.6.2015. https://CRAN.R-project.org/package=data.table Accessed October 06, 2016.
30. Wickham H, ed. Elegant Graphics for Data Analysis. New York, NY: Springer-Verlag; 2009.
31. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510-e526. doi: 10.1161/CIRCULATIONAHA.108.189141.
32. Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-Analytic review of the Necessity-Concerns Framework. PLoS One. 2013;8:e80633. doi: 10.1371/journal.pone.0080633.
33. WHO. Adherence to long-term therapies: evidence for action. www.who. int/chp/knowledge/publications/adherence-full-report.pdf. Accessed December 12, 2016.
34. NICE. NICE Clinical Guideline 76: medicines adherence. www.nice.org. uk/CG76. Accessed April 5, 2017.
35. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427. doi: 10.1136/bmj.326.7404.1427.
36. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev. 2004;2:CD004804.
37. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:CD000011.
38. Viswanathan M, Kahwati LC, Golin CE, Blalock SJ, Coker-Schwimmer E, Posey R, Lohr KN. Medication therapy management interventions in outpatient settings: a systematic review and meta-Analysis. JAMA Intern Med. 2015;175:76-87. doi: 10.1001/jamainternmed.2014.5841.
39. Koçkaya G, Wertheimer A. Can we reduce the cost of illness with more compliant patients? An estimation of the effect of 100% compliance with hypertension treatment. J Pharm Pract. 2011;24:345-350. doi: 10.1177/0897190010389336.
40. IMS Institute of Healthcare Informatics. Avoidable costs in US health care. www.imshealth.com/en-ZA/thought-leadership/ims-institute/reports/avoidable-costs. Accessed February 23, 2017.
41. Molloy GJ, Messerli-Bürgy N, Hutton G, Wikman A, Perkins-Porras L, Steptoe A. Intentional and unintentional non-Adherence to medications following an acute coronary syndrome: a longitudinal study. J Psychosom Res. 2014;76:430-432. doi: 10.1016/j.jpsychores.2014.02.007.
42. Pucci M, Martin U. Detecting non-Adherence by urine analysis in patients with uncontrolled hypertension: rates, reasons and reactions. J Hum Hypertens. 2017;31:253-257. doi: 10.1038/jhh.2016.69.
43. Chatterjee JS. From compliance to concordance in diabetes. J Med Ethics. 2006;32:507-510. doi: 10.1136/jme.2005.012138.